Synergy CHC Corp. announced on June 18, 2025, an expansion of its international licensing deal with Gravity Pharma. This agreement adds Turkey alongside the United Arab Emirates (UAE) for the exclusive distribution of FOCUSfactor®.
This strategic move brings total upfront licensing revenue to $2 million for Synergy CHC Corp. Additionally, the agreement includes provisions for performance-based royalties tied to product sales across both high-growth markets.
This expansion underscores Synergy's commitment to broadening the global footprint of its FOCUSfactor brand. It positions the company to capitalize on increasing demand for health and wellness products in these regions and establish new revenue streams.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.